Scholarlink

<p>The intestinal microbiome shapes immune responses and is associated with patient outcomes in cancer following immunotherapy. We evaluated differences between the intestinal microbiome profiles of patients with early-stage invasive breast cancer (BC) and ductal carcinoma in situ (DCIS) by subtype using whole genome metagenomic sequencing. There were no significant differences in microbiome composition between DCIS and invasive BC as measured by alpha diversity (<i>p</i> = 0.20, ANOVA) or beta diversity (<i>p</i> = 0.52, PERMANOVA). Within invasive BC, patients with hormone receptor-positive (HR + )/HER2 + BC differed significantly in beta diversity relative to other subtypes (<i>p</i> &lt; 0.05), with differences in six species (<i>q</i> &lt; 0.25). <i>Bacteroides ovatus</i> was significantly more abundant in patients with stage III BC vs. stage I (<i>p</i> = 0.0003). Functional pathway analysis using HUMAnN3 revealed stage-specific enrichment of amino acid biosynthesis and nucleotide-related pathways. Altogether, these findings highlight potential microbial signatures associated with BC subtype and stage.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月27日

查看全文
  • Sarah L. Sammons,
  • Thomas M. Kuntz,
  • Molly DiLullo,
  • Xochitl C. Morgan,
  • Alyssa Martin,
  • Melissa E. Hughes,
  • Tasnim Rahman,
  • Romualdo Barroso-Sousa,
  • Esther Ritah Ogayo,
  • Julia Giordano,
  • Sean Ryan,
  • Adrienne G. Waks,
  • Ilana Schlam,
  • Jennifer Ligibel,
  • Nancy U. Lin,
  • Ana C. Garrido-Castro,
  • Elizabeth A. Mittendorf,
  • Sara M. Tolaney

摘要

The intestinal microbiome shapes immune responses and is associated with patient outcomes in cancer following immunotherapy. We evaluated differences between the intestinal microbiome profiles of patients with early-stage invasive breast cancer (BC) and ductal carcinoma in situ (DCIS) by subtype using whole genome metagenomic sequencing. There were no significant differences in microbiome composition between DCIS and invasive BC as measured by alpha diversity (p = 0.20, ANOVA) or beta diversity (p = 0.52, PERMANOVA). Within invasive BC, patients with hormone receptor-positive (HR + )/HER2 + BC differed significantly in beta diversity relative to other subtypes (p < 0.05), with differences in six species (q < 0.25). Bacteroides ovatus was significantly more abundant in patients with stage III BC vs. stage I (p = 0.0003). Functional pathway analysis using HUMAnN3 revealed stage-specific enrichment of amino acid biosynthesis and nucleotide-related pathways. Altogether, these findings highlight potential microbial signatures associated with BC subtype and stage.